Get the Stockscreener App
1.14
21.24%
0.1997
After Hours:
1.09
-0.05
-4.39%
Applied Therapeutics Inc stock is traded at $1.14, with a volume of 4.04M.
It is up +21.24% in the last 24 hours and up +171.04% over the past month.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
See More
Previous Close:
$0.9403
Open:
$0.95
24h Volume:
4.04M
Relative Volume:
0.92
Market Cap:
$164.17M
Revenue:
-
Net Income/Loss:
$-119.76M
P/E Ratio:
-0.8444
EPS:
-1.35
Net Cash Flow:
$-55.17M
1W Performance:
+11.76%
1M Performance:
+171.04%
6M Performance:
+206.78%
1Y Performance:
-86.70%
1-Day Range:
$0.9004
$1.165
1-Week Range:
$0.9004
$1.19
52-Week Range:
$0.295
$10.62
Applied Therapeutics Inc Stock (APLT) Company Profile
Name
Applied Therapeutics Inc
Sector
Industry
Phone
212-220-9226
Address
545 FIFTH AVENUE, SUITE 1400, NEW YORK, NY
Compare APLT with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
APLT
Applied Therapeutics Inc
|
1.14 | 135.41M | 0 | -119.76M | -55.17M | -1.35 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.37 | 104.55B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
464.95 | 60.36B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
557.73 | 59.84B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
799.56 | 49.07B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
327.03 | 35.16B | 4.56B | -176.77M | 225.30M | -1.7177 |
Applied Therapeutics Inc Stock (APLT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Dec-23-24 | Downgrade | William Blair | Outperform → Mkt Perform |
| Dec-02-24 | Downgrade | UBS | Buy → Neutral |
| Nov-29-24 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| Jul-31-24 | Initiated | William Blair | Outperform |
| Mar-26-24 | Initiated | RBC Capital Mkts | Outperform |
| Feb-22-24 | Initiated | Leerink Partners | Outperform |
| Jan-04-22 | Downgrade | Barclays | Overweight → Equal Weight |
| Aug-27-21 | Downgrade | Goldman | Neutral → Sell |
| Jun-25-21 | Resumed | Goldman | Neutral |
| Oct-08-20 | Initiated | Truist | Buy |
| Apr-22-20 | Initiated | Goldman | Buy |
| Feb-27-20 | Initiated | Barclays | Overweight |
| Jun-10-19 | Initiated | Citigroup | Buy |
| Jun-10-19 | Initiated | Cowen | Outperform |
| Jun-10-19 | Initiated | Robert W. Baird | Outperform |
View All
Applied Therapeutics Inc Stock (APLT) Latest News
What the charts say about Applied Therapeutics Inc. todayWeekly Trend Summary & Low Risk Entry Point Guides - newser.com
How to use Fibonacci retracement on Applied Therapeutics Inc.Quarterly Market Summary & Safe Capital Growth Trade Ideas - newser.com
Is Applied Therapeutics Inc. stock reversal real or fakeJuly 2025 Spike Watch & Reliable Price Breakout Alerts - newser.com
How Applied Therapeutics Inc. stock compares to industry benchmarksWeekly Earnings Recap & Daily Risk Controlled Trade Plans - newser.com
Will Applied Therapeutics Inc. stock reach all time highs in 2025Trade Volume Summary & Accurate Trade Setup Notifications - newser.com
Applied Therapeutics Inc. (NASDAQ:APLT) Receives Average Recommendation of "Hold" from Brokerages - MarketBeat
Applied Therapeutics Inc Stock Analysis and ForecastStock Price Targets & Optimize Entry & Exit With Smart Signals - earlytimes.in
Applied Therapeutics Inc. stock trendline breakdownJuly 2025 EndofMonth & Growth Oriented Trading Recommendations - newser.com
Can Applied Therapeutics Inc. hit a new high this monthWeekly Stock Report & High Yield Stock Recommendations - newser.com
Why retail investors favor Applied Therapeutics Inc. stockWeekly Trade Report & Weekly Breakout Watchlists - newser.com
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Shareholders to Inquire about Securities Investigation - ACCESS Newswire
How strong is Applied Therapeutics Inc. stock revenue growthJuly 2025 Macro Moves & Reliable Volume Spike Trade Alerts - newser.com
Earnings visualization tools for Applied Therapeutics Inc.CPI Data & Accurate Entry and Exit Point Alerts - newser.com
Will Applied Therapeutics Inc. stock benefit from automationJuly 2025 PreEarnings & Fast Gaining Stock Reports - newser.com
What drives Applied Therapeutics Inc stock priceAI-Driven Market Analysis & Maximum Profit Growth - earlytimes.in
Is Applied Therapeutics Inc a good long term investmentIPO Market Watch & Budget Friendly Growth Tips - earlytimes.in
4 Biotech Stocks Seeing Explosive Momentum GainsAldeyra Therapeutics (NASDAQ:ALDX) - Benzinga
After losing 87% in the past year, Applied Therapeutics, Inc. (NASDAQ:APLT) institutional owners must be relieved by the recent gain - simplywall.st
Applied Therapeutics Settled With Investors Over Govorestat FDA Rejection – How to Claim Your Payout - TradingView
Why Applied Therapeutics Inc. is moving todayEarnings Summary Report & Community Supported Trade Ideas - newser.com
Will Applied Therapeutics Inc. continue its uptrendTrade Volume Report & Free Technical Confirmation Trade Alerts - newser.com
Detecting price anomalies in Applied Therapeutics Inc. with AIEarnings Overview Report & Safe Entry Momentum Stock Tips - newser.com
Is Applied Therapeutics Inc. stock near bottom after declineQuarterly Trade Review & Consistent Income Trade Ideas - newser.com
Institutional investors may adopt severe steps after Applied Therapeutics, Inc.'s (NASDAQ:APLT) latest 19% drop adds to a year losses - Yahoo Finance
Custom strategy builders for tracking Applied Therapeutics Inc.Quarterly Risk Review & Expert Curated Trade Setup Alerts - newser.com
What analysts say about Applied Therapeutics Inc stockMarket Sentiment Shifts & Optimize Entry & Exit With Smart Signals - earlytimes.in
Are Analysts Raising Price Targets for Can Fin Homes Limited AgainValue Stock Picks & Demo Trading Rooms Open Daily - earlytimes.in
APLT LAWSUIT ALERT: Levi & Korsinsky Notifies Applied Therapeutics, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - ACCESS Newswire
How Applied Therapeutics Inc. stock trades during market volatilityGold Moves & Weekly Top Gainers Alerts - newser.com
Applied Therapeutics, Inc. (APLT) Investigation: Bronstein, Gewirtz & Grossman, LLC Encourages Shareholders to Contact the Firm to Learn More About the Investigation - ACCESS Newswire
Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Stockholders to Inquire about Securities Investigation - ACCESS Newswire
2025-09-30 | Bronstein, Gewirtz & Grossman, LLC Encourages Applied Therapeutics, Inc. (APLT) Stockholders to Inquire about Securities Investigation | NDAQ:APLT | Press Release - Stockhouse
Can SMIFS Capital Markets Limited Stock Deliver Alpha in a Choppy MarketCovered Call Writing & No Fee. No Catch. Just Smart Investment Ideas - earlytimes.in
Promising Penny Stocks To Follow Now – September 27th - Defense World
Applied Therapeutics Inc. $APLT Shares Sold by Goldman Sachs Group Inc. - MarketBeat
Applied Therapeutics Inc Stock (APLT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Applied Therapeutics Inc Stock (APLT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Funtleyder Leslie D. | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
14,502 |
6,381 |
390,459 |
| Chinoporos Constantine | See Remarks |
Mar 04 '25 |
Sale |
0.44 |
447 |
197 |
271,436 |
| Funtleyder Leslie D. | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
22,950 |
14,000 |
404,961 |
| Perfetti Riccardo | Chief Medical Officer |
Feb 06 '25 |
Sale |
0.61 |
86,078 |
52,508 |
900,775 |
| Chinoporos Constantine | See Remarks |
Feb 06 '25 |
Sale |
0.61 |
28,117 |
17,151 |
271,883 |
1.11%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):